Schrödinger

In a recent paper published in Nature Structural & Molecular Biology, researchers from UCB Pharma and University of Pittsburgh used FEP+ to refine and validate cryo-electron microscopy structures of SV2A and SV2B, proteins important in the treatment of epilepsy. FEP+ is Schrödinger’s proprietary, physics-based free energy perturbation technology for computationally predicting protein-ligand binding at an accuracy approaching experimental methods. In the paper, researchers describe using FEP+ to differentiate between correct and incorrect small molecule binding modes when solving cryo-EM complex structures. Read the paper: https://hubs.li/Q02FJGCH0 Learn more about FEP+: https://hubs.li/Q02FJKj30

Congratulations to our partner Morphic Therapeutic, a company that Schrödinger co-founded, on their planned acquisition by Eli Lilly. We are proud to have partnered side-by-side on the discovery of several programs, including MORF-057, that have the potential to transform patient care, and Morphic has been one of our largest and longest-standing customers in the biotech community.

Are you attending the Institute of Food Technologists Conference taking place on July 14th – 17th in Chicago, Illinois? Join us for a presentation by Schrödinger's Jeffrey Sanders exploring how food scientists can leverage physics-based modeling and machine learning to make more informed decisions when formulating new foods and beverages with alternative proteins. Stop by our booth #2125 to discuss your food R&D challenges with our scientists. Learn more: https://hubs.li/Q02F2Bxb0 #Schrodinger #DigitalChemistry #MaterialsScience #Food

Schrödinger is proud to support and encourage gender equity through the work of our Gender Diversity Action Committee. Thank you to the 25 women and non-binary computational scientists who were selected to attend our two-day symposium earlier this month! Attendees shared their PhD and post-doc research projects, networked with Schrödinger scientists, and participated in interactive molecular modeling workshops and resume feedback sessions. Interested in a career at Schrödinger? View our open positions: https://hubs.li/Q02Dv9gn0 Learn more about our commitment to diversity, equity, and inclusion in our inaugural corporate sustainability report: https://hubs.li/Q02Dv8rW0 #schrodingergenderequity #STEMeducation #schrodinger #sdgr #womeninSTEM #womeninscience #DEI #diversityinSTEM #nonbinaryscientist #womenintech #nonbinaryinSTEM

Register now for Schrödinger's upcoming US User Group Meeting, taking place on September 17-18, 2024 at Vintners Resort in Santa Rosa, California. Join us for this in-person event convening Schrödinger team members and customers for a two-day, interactive program that includes scientific presentations, workshops, and panel discussions, as well as networking opportunities and evening social events. We look forward to seeing you there! Register here: https://hubs.li/Q02Dpv2w0

Join us at the 38th ACS National Medicinal Chemistry Symposium taking place on June 23rd – 26th in Seattle, Washington. Don't miss the presentation by Schrödinger's Jennifer Knight exploring how machine learning can drive innovation in your drug discovery pipeline. Participate in a hands-on workshop using Schrödinger’s LiveDesign platform to design and triage DLK inhibitors using a series of predictive models. Learn more: https://hubs.li/Q02CVzry0

While lithium-ion battery technology has revolutionized many industries, new chemistries are needed to address the growing demand for greater power density, safety, reliability, and battery life. Join Schrödinger’s Dr. Garvit Agarwal on June 26th for a webinar exploring the key materials challenges for improving battery performance. Learn how atomistic simulation and machine learning enable rapid screening of battery materials to accelerate the development of novel technology. Register here: https://hubs.li/Q02CJmWk0 #Schrodinger #DigitalChemistry #MaterialsScience #Batteries

FEP+ is a powerful predictive technology in drug discovery with applications from hit discovery through lead optimization. A critical first step in deploying FEP+ is to validate and optimize the model for the protein-ligand system of interest. Join us on June 25th for a webinar exploring Schrödinger’s FEP Protocol Builder, an automated machine learning workflow for FEP+ model optimization. FEP Protocol Builder saves researcher time by efficiently identifying an optimized predictive model for your system of interest. Register now: https://hubs.li/Q02BQ9rd0

Thank you to Schrödinger's Karen Akinsanya and co-panelists for the compelling conversation at #BIO2024 exploring the impact of machine learning on drug discovery and R&D. In case you missed it, here's a snippet from the panel discussion: “The opportunity ahead of us is this extraordinarily powerful new tool in our toolbox that allows us to do science at scale. Machine learning will allow us to leverage and build upon decades of investment that have gone into the scaling up of biology and experimentation," stated Karen Akinsanya, president of R&D, therapeutics. "At Schrödinger, in compound design we are routinely scoring billions of compounds on a single target program using physics to find the optimal molecule with great properties in the multi-parameter optimization problem. It's really that ability to scale the physics with machine learning that enables this new approach.”

Need help obtaining funding for a Schrödinger Online Course? We proudly support the next generation of scientists and are committed to providing opportunities to those with limited resources. Learn about your funding options for our online certification courses as a student, post-doc, or industry scientist and enroll today! Click to learn more: https://hubs.li/Q02BbbtX0